Track Adaptimmune Therapeutics plc — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Adaptimmune Therapeutics plc ADAPY · Stock Open Adaptimmune Therapeutics plc in new tab

0.0300 USD
EPS
-0.67
P/B
0.31
ROE
-346.65
Beta
0.82
Loading chart...
Key Metrics
Earnings dateNov. 12, 2026
EPS-0.67
Book Value0.12
Price to Book0.31
Debt/Equity44.05
% Insiders0.631%

DCF Valuation

Tweak assumptions to recompute fair value for Adaptimmune Therapeutics plc (ADAPY)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result

Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Adaptimmune Therapeutics plc Logo Adaptimmune Therapeutics plc Analysis (ADAPY)

USA Official Website Stock

Is Adaptimmune Therapeutics plc a good investment? Adaptimmune Therapeutics plc (ADAPY) is currently trading at 0.0300 USD.

Earnings Schedule: Adaptimmune Therapeutics plc is expected to release its next earnings report on Nov. 12, 2026.

Investor FAQ

Does Adaptimmune Therapeutics plc pay a dividend?

No, it does not currently pay a dividend.

What asset class is Adaptimmune Therapeutics plc?

Adaptimmune Therapeutics plc is classified as a Stock.

When is the next earnings date?

The next earnings date is projected to be Nov. 12, 2026. The company currently has a trailing EPS of -0.67.

Company Profile

Adaptimmune Therapeutics plc engages in research, development, and subsequent manufacture and commercialisation of cell therapies to treat cancer in the United States and the United Kingdom. The company was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion